{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.1","upperLimit":"62.9","value":"58.0"},{"groupId":"OG001","lowerLimit":"30.9","upperLimit":"44.7","value":"37.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"NUMBER","populationDescription":"ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.","reportingStatus":"POSTED","timeFrame":"34.6 months","title":"CBR Per RECIST 1.1 as Determined by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}